•
Jun 30, 2024

Ecolab Q2 2024 Earnings Report

Ecolab demonstrated strong financial performance in Q2 2024, marked by sales growth, margin expansion, and increased earnings per share.

Key Takeaways

Ecolab reported a 3% increase in sales to $4.0 billion, with organic sales up 4%. The company's adjusted EPS grew by 35% to $1.68, driven by strong operating income margin expansion. Ecolab also raised its full-year adjusted EPS outlook to $6.50 - $6.70.

Reported sales reached $4.0 billion, a 3% increase year-over-year, with a 1% headwind from unfavorable foreign currency exchange.

Organic sales grew by 4%, with the Institutional & Specialty segment normalizing to a strong 7% growth.

Reported operating income margin was 16.5%, while organic operating income margin expanded by 360 bps to 17.0%.

Adjusted diluted EPS increased by 35% to $1.68, excluding special gains, charges, and discrete tax items.

Total Revenue
$3.99B
Previous year: $3.85B
+3.5%
EPS
$1.68
Previous year: $1.24
+35.5%
Operating Income Margin
16.5%
Previous year: 12.6%
+31.0%
Gross Profit
$1.74B
Previous year: $1.52B
+15.0%
Cash and Equivalents
$384M
Previous year: $554M
-30.7%
Free Cash Flow
$414M
Previous year: $401M
+3.2%
Total Assets
$21.5B
Previous year: $21.5B
+0.0%

Ecolab

Ecolab

Ecolab Revenue by Segment

Forward Guidance

Ecolab anticipates full-year 2024 adjusted diluted earnings per share to be in the range of $6.50 to $6.70, reflecting a 25% to 29% increase compared to 2023.

Positive Outlook

  • Continued solid sales growth, driven by value pricing and new business gains.
  • Attractive organic operating income margin expansion, driven by robust increases in gross margin.
  • Good underlying productivity.
  • Quarterly adjusted diluted earnings per share growth to progressively normalize towards the company’s long-term 12-15% target as solid growth continues.
  • Impacts from delivered product costs are anticipated to normalize exiting 2024.

Challenges Ahead

  • Unfavorable impact in the second half of 2024 from the sale of Ecolab’s global surgical solutions business, estimated to be $0.08 per share.
  • Soft but stable macroeconomic demand.
  • Favorability from delivered product costs that eases through the third quarter of 2024.
  • Impact of global inflation remains hard to predict.
  • Good underlying productivity is expected to be offset in the short-term by growth-oriented investments in the business to fuel Ecolab’s long-term performance.

Revenue & Expenses

Visualization of income flow from segment revenue to net income